Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD33-Targeted CAR-T in Myeloid Malignancies
NCT02958397Phase 2Unknown
- Sponsor
- Southwest Health System
- Start
- Oct 2016
- Primary completion
- Oct 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CD33 CAR-T cells in myeloid malignancies, sponsored by Southwest Health System. Primary endpoint: Adverse Events That Are Related to Treatment at 3 years. Status: unknown.
02
Drugs
anti-CD33 CAR-T cells
03
Conditions
myeloid malignancies
Beyond the preview
Go deeper on NCT02958397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958397.